Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics, Inc. - Common Stock (NQ:HOWL)

0.9292 +0.0392 (+4.40%)
Streaming Delayed Price Updated: 12:08 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Werewolf Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today? ↗
Werewolf Therapeutics stock is taking off with heavy trading of HOWL shares after posting preliminary data from a clinical trial. 
Via InvestorPlace
News headline image
Werewolf Therapeutics' Cancer Drug Shows Promise in Early Study for Solid Tumors, Stock Soars ↗
Werewolf Therapeutics Inc (NASDAQ: HOWL) released preliminary results from initial monotherapy dose-escalation cohorts of an ongoing Phase 1/1b trial of WTX-124 in patients with advanced or  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Ratings for Werewolf Therapeutics ↗
 
Via Benzinga
News headline image
Recap: Werewolf Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
Analyst Ratings for Werewolf Therapeutics ↗
 
Via Benzinga
News headline image
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders. 
Via Benzinga
News headline image
Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket ↗
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning! 
Via InvestorPlace
News headline image
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are a hot topic among traders on Thursday and we're offering all of the latest coverage this morning! 
Via InvestorPlace
News headline image
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET 
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Small Cancer Player Werewolf Therapeutics' Stock Undervalued: Analyst Says Treatment Platform Underappreciated ↗
Wedbush initiated coverage on Werewolf Therapeutics Inc (NASDAQ: HOWL) with an Outperform rating and a  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023 ↗
 
Via Benzinga
News headline image
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Participate in May Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
News headline image
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.